ArticleAdvances in ophthalmology practice and research
Efficacy and safety of ultrasound cycloplasty as the first treatment in glaucoma for eyes with functional vision: A 1-year prospective study.
Article in Advances in ophthalmology practice and research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of ultrasound cycloplasty on ocular biomechanics and refractive parameters: a comprehensive review.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Ultrasound cycloplasty (UCP) is a non-invasive treatment traditionally used for advanced glaucoma. However, its potential as the first surgical option for moderate glaucoma with functional vision has not been thoroughly investigated. This study aimed to assess the effectiveness and safety of UCP as the initial surgery for glaucoma with residual visual function. Methods: This prospective study included 117 glaucoma patients (63 males, 54 females; mean age 48.3 ± 17.2 years) with various glaucoma subtypes and best-corrected visual acuity (BCVA) better than 1.30 logMAR who underwent UCP as their first treatment. The primary outcomes were the surgical success rates at 12 months for both qualified and complete success. Qualified success was defined as a ≥20% reduction in intraocular pressure (IOP) from baseline, IOP between 6 and 21 mmHg, and no additional glaucoma surgery, achieved with or without anti-glaucoma medication. Complete success was defined by the same criteria, but achieved without any anti-glaucoma medications. Secondary outcomes included mean IOP, BCVA, and postoperative complications. Results: The qualified success rate of UCP as the first treatment was 71.8% at 12 months, with a complete success rate (medication-free) of 27.4%. Subgroup analysis revealed that PACG had the highest qualified success rate (84.8%), followed by POAG (73.0%) and NVG (66.7%). Patients with ≤0.30 logMAR achieved the highest rate (80.0%), followed by those with 0.30-0.50 logMAR (75.0%), 0.50-1.00 logMAR (66.7%), and 1.00-1.30 logMAR (63.6%). The overall mean BCVA showed minimal change from 0.62 ± 0.42 logMAR at baseline to 0.63 ± 0.43 logMAR at 1 year. Patients experienced initial visual acuity decline in the early postoperative period, which gradually recovered after 1 week. Only 2.6% (3/117) of patients experienced a clinically significant visual decline of more than 2 lines at 12-month follow-up. No severe complications were observed. Conclusions: UCP can be an effective and safe option as the first surgical treatment for glaucoma patients with visual function. UCP significantly reduces IOP over 12 months without causing significant visual acuity decline or severe complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.